Patterns of CRS with teclistamab in relapsed/refractory multiple myeloma with or without prior T-cell redirection therapy.

Although grade 2 CRS rates were higher in cohort 2 compared to cohort 1, the difference did not reach statistical significance ( Figure 2 B).

also in 111,027 other papers